Company profile CRVS

Corvus Pharmaceuticals Inc
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
Quarter analysis & expected interestLast update: February 09 2024 17:12:15.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Corvus Pharmaceuticals expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201946
91
97.8% QoQ
161
76.9% QoQ
80
-50.3% QoQ
2020 71
54.3% YoY -11.2% QoQ
78
-14.3% YoY 9.9% QoQ
140
-13.0% YoY 79.5% QoQ
49
-38.8% YoY -65.0% QoQ
2021 106
49.3% YoY 116.3% QoQ
107
37.2% YoY 0.9% QoQ
171
22.1% YoY 59.8% QoQ
33
-32.7% YoY -80.7% QoQ
2022 54
-49.1% YoY 63.6% QoQ
77
-28.0% YoY 42.6% QoQ
128
-25.1% YoY 66.2% QoQ
61
84.8% YoY -52.3% QoQ
2023 31
-42.6% YoY -49.2% QoQ
67
-13.0% YoY 116.1% QoQ
93
-27.3% YoY 38.8% QoQ
71
16.4% YoY -23.7% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Corvus Pharmaceuticals search interestLast update: February 09 2024 17:12:14.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 17:12:15.

The average 5 years interest of Corvus Pharmaceuticals was 6.57 per week.
The last year interest of Corvus Pharmaceuticals compared to the last 5 years has changed by -29.22%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -40.15%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 17:12:20.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Corvus Pharmaceuticals stock expected interest is significantly lower compared to previous quarter (-100.0%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019113
111
-1.8% QoQ
52
-53.2% QoQ
59
13.5% QoQ
2020 89
-21.2% YoY 50.8% QoQ
118
6.3% YoY 32.6% QoQ
201
286.5% YoY 70.3% QoQ
84
42.4% YoY -58.2% QoQ
2021 97
9.0% YoY 15.5% QoQ
103
-12.7% YoY 6.2% QoQ
217
8.0% YoY 110.7% QoQ
129
53.6% YoY -40.6% QoQ
2022 122
25.8% YoY -5.4% QoQ
0
-100.0% YoY -100.0% QoQ
92
-57.6% YoY inf% QoQ
133
3.1% YoY 44.6% QoQ
2023 0
-100.0% YoY -100.0% QoQ
97
inf% YoY inf% QoQ
101
9.8% YoY 4.1% QoQ
46
-65.4% YoY -54.5% QoQ
2024 0
-65.4% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Corvus Pharmaceuticals stock search interestLast update: February 09 2024 17:12:20.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 17:12:21.

The average 5 years interest of Corvus Pharmaceuticals stock was 7.52 per week.
The last year interest of Corvus Pharmaceuticals stock compared to the last 5 years has changed by -37.63%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -31.13%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 17:12:29.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Corvus Pharmaceuticals news expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201989
145
62.9% QoQ
188
29.7% QoQ
0
-100.0% QoQ
2020 0
-100.0% YoY -100.0% QoQ
57
-60.7% YoY inf% QoQ
113
-39.9% YoY 98.2% QoQ
96
inf% YoY -15.0% QoQ
2021 139
inf% YoY 44.8% QoQ
68
19.3% YoY -51.1% QoQ
136
20.4% YoY 100.0% QoQ
259
169.8% YoY 90.4% QoQ
2022 96
-30.9% YoY -62.9% QoQ
162
138.2% YoY 68.8% QoQ
26
-80.9% YoY -84.0% QoQ
45
-82.6% YoY 73.1% QoQ
2023 197
105.2% YoY 337.8% QoQ
0
-100.0% YoY -100.0% QoQ
81
211.5% YoY inf% QoQ
205
355.6% YoY 153.1% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Corvus Pharmaceuticals news search interestLast update: February 09 2024 17:12:28.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 17:12:31.

The average 5 years interest of Corvus Pharmaceuticals news was 8.05 per week.
The last year interest of Corvus Pharmaceuticals news compared to the last 5 years has changed by -2.11%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -2.96%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for CPI-006 immuno-oncology therapy to provide analysis

Correlation between past revenue and CPI-006 immuno-oncology therapy search interest

There is not enough data for CPI-006 immuno-oncology therapy to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for CPI-006 immuno-oncology therapy to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for CPI-006 clinical trial to provide analysis

Correlation between past revenue and CPI-006 clinical trial search interest

There is not enough data for CPI-006 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for CPI-006 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for CPI-818 ITK inhibitor to provide analysis

Correlation between past revenue and CPI-818 ITK inhibitor search interest

There is not enough data for CPI-818 ITK inhibitor to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for CPI-818 ITK inhibitor to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for CPI-818 clinical trial to provide analysis

Correlation between past revenue and CPI-818 clinical trial search interest

There is not enough data for CPI-818 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for CPI-818 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for CPI-444 A2A receptor antagonist to provide analysis

Correlation between past revenue and CPI-444 A2A receptor antagonist search interest

There is not enough data for CPI-444 A2A receptor antagonist to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for CPI-444 A2A receptor antagonist to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for CPI-444 clinical trial to provide analysis

Correlation between past revenue and CPI-444 clinical trial search interest

There is not enough data for CPI-444 clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for CPI-444 clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Corvus Pharmaceuticals headquarters to provide analysis

Correlation between past revenue and Corvus Pharmaceuticals headquarters search interest

There is not enough data for Corvus Pharmaceuticals headquarters to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Corvus Pharmaceuticals headquarters to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for CRVS
Earnings date: 2024-03-07 After close
Company name: Corvus Pharmaceuticals Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-14T11:00:00Z

GlobeNewswire
Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting

2026-05-07T20:01:00Z

GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results

2026-04-24T16:16:27-04:00

SEC
DEFA14A Form - Additional definitive proxy soliciting materials and Rule 14(a)(12) material - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

2026-04-24T16:15:31-04:00

SEC
DEF 14A Form - Other definitive proxy statements - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

2026-04-23T11:30:00Z

GlobeNewswire
Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors

2026-04-21T11:30:00Z

GlobeNewswire
Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting

2026-04-17T11:41:22Z

Analyst Upgrades
Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40

2026-03-12T20:01:00Z

GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

2026-03-05T21:01:00Z

GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

2026-02-23T21:01:00Z

GlobeNewswire
Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

2026-01-23T22:00:15Z

GlobeNewswire
Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

2026-01-22T20:24:00Z

Analyst Upgrades
Jefferies Maintains Buy on Corvus Pharma, Raises Price Target to $42

2026-01-22T03:53:56Z

GlobeNewswire
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

2026-01-21T17:59:22Z

Analyst Upgrades
Oppenheimer Maintains Outperform on Corvus Pharma, Raises Price Target to $32

2026-01-21T14:28:34Z

Analyst Upgrades
Barclays Maintains Overweight on Corvus Pharma, Raises Price Target to $28